6 news items
Aurinia Issues Letter To Shareholders In Response To Letter From Shareholder Lucien Selce; Company Raises Concerns Surrounding Lucien Selce's Lack Of Credibility
AUPH
4 Jun 24
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
AUPH
4 Jun 24
) (Aurinia or the Company) today issued the following letter to shareholders in response to a letter from Lucien Selce
Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf
AUPH
3 Jun 24
compensation. In its report, ISS noted the Board's compensation committee "demonstrated poor responsiveness to shareholder concerns following last year's failed
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024
AUPH
14 May 24
sustained complete renal response and reductions in steroid use over three years of treatment, compared to MMF and steroids alone," said Dr. Greg Keenan
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
AUPH
9 May 24
.
A post-hoc analysis showed Black patients experienced improved outcomes and better renal response when using
05iwd33no8e7 kgpzqa9zr8dm2megedvnyews7r
AUPH
2 May 24
complete renal response at every time point assessed through three years, compared to mycophenolate mofetil (MMF) and low-dose glucocorticoids alone
- Prev
- 1
- Next